<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[aranesp Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/aranesp.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to aranesp]]></description>
	<s:counts start="0" returned="15" found="15" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Amgen, Aranesp, and anemia patients get the bad news]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/amgen-aranesp-anemia-patients-news/18588/]]></link>
		<description><![CDATA[]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Mon, 02 Nov 2009 15:13:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[trial]]></category>
		<category domain="http://resources.bnet.com/topic/cancer.html"><![CDATA[cancer]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[EU Commission Approves Updated Prescribing Information for Aranesp®]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_5/ai_n24363721]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen (NASDAQ: AMGN) today announced that the European Commission reached its final decision to amend the prescribing information for Aranesp([R]) darbepoetin alfa based on the positive opinion from the European Committee for Medicinal Products for Human Use CHMP in January 2008. The CHMP granted positive opinions...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 05 Mar 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/european+commission.html"><![CDATA[European Commission]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Jan_29/ai_n24234852]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) issued the following statement on the publication of an Aranesp([R]) darbepoetin alfa manuscript in the January 28, 2008, online issue of the Journal of Clinical Oncology. Amgen anticipates this manuscript will be available in the March 1, 2008, print edition.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 29 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/manuscript.html"><![CDATA[manuscript]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Announces Interim Results of Aranesp® "PREPARE" Study in Breast Cancer Patients]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Nov_30/ai_n21131269]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen, Inc. (NASDAQ: AMGN) today announced that it had received interim results from the independent investigator-sponsored "PREPARE" study, an open-label, randomized, multicenter Phase 3 study of Aranesp([R]) darbepoetin alfa in 733 neoadjuvant breast cancer patients receiving dose-dense, dose-intense preoperative chemotherapy compared to a standard preoperative chemotherapy...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 30 Nov 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/breast+cancer.html"><![CDATA[breast cancer]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp®]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Sept_27/ai_n27388830]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) today announced that the European Medicines Agency's EMEA Committee for Medicinal Products for Human Use CHMP has communicated to Marketing Authorization Holders MAHs of epoetins a proposal for amending prescribing information for Erythropoiesis Stimulating Agents ESAs in the European Union, including Aranesp([R]) darbepoetin alfa.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 27 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_5/ai_n27074046]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN), today posted to its corporate web site documents intended to clarify Amgen's position on the use of EPOGEN([R]) Epoetin alfa and Aranesp([R]) darbepoetin alfa and to correct what the company believes are misleading and inaccurate news reports regarding the use of its drugs. Amgen's...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 05 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Receives Complete Response Letter for Extended Dosing of Aranesp® for Patients with Chronic Kidney Disease and Anemia]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Oct_13/ai_n27039276]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration FDA has issued a complete response letter, commonly referred to as an "approvable" letter, for Aranesp[R] darbepoetin alfa de novo once every-two-week and maintenance once-monthly dosing regimens for chronic kidney disease CKD patients with anemia...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 13 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[FDA Approves Extended Dosing of Aranesp® to Treat Chemotherapy-Induced Anemia; Every-Three-Week Dosing Can Provide Added Convenience, Potentially Reducing Number of Clinic Visits and Injections for Anemia Treatment]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_March_27/ai_n16112942]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration FDA has approved every-three-week dosing of AranespR darbepoetin alfa for the treatment of chemotherapy-induced anemia low red blood cell count in patients with non-myeloid malignancies. Aranesp is the only erythropoiesis-stimulating agent...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Mar 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Amgen Submits Supplemental Biologics License Application for Aranesp Extended Dosing; Phase 3 Study Evaluated Aranesp Dosed Once Every Three Weeks in Patients with Chemotherapy-Induced Anemia]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_May_6/ai_n13674959]]></link>
		<description><![CDATA[THOUSAND OAKS, Calif. -- Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology company, today announced the submission of a supplemental Biologics License Application sBLA to the U.S. Food and Drug Administration FDA for AranespR darbepoetin alfa. The sBLA is based on Phase 3 data that Amgen believes will demonstrate Aranesp administered...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 06 May 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/anemia.html"><![CDATA[anemia]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen posts solid first quarter from Neulasta and Aranesp sales. (Markets: Life Sciences).]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200304/ai_n13360594]]></link>
		<description><![CDATA[AMGEN INC. posted solid first quarter results on strong sales of  second-generation drugs Neulasta pegfilgrastim and Aranesp  darbepoetin alfa. Amgen projects earnings per share for 2003 of $1.80  to $1.90 versus its previous estimate of $1.70 to     AMGEN INC. posted solid first quarter...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 28 Apr 2003 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/life+science.html"><![CDATA[life science]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[sales]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Ventura County Star, Calif., Business Briefs Column.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5553/is_200209/ai_n21668680]]></link>
		<description><![CDATA[Ventura County Star, Calif. Knight Ridder/Tribune Business News    Sep. 5--AMGEN DRUG OK'D FOR SALE IN BRITISH COLUMBIA: British  Columbia  regulators have given Amgen permission to sell its new  extended-release drug  Aranesp for treatment of anemia associated with  chronic kidney disease.  ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 05 Sep 2002 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/admission.html"><![CDATA[Admission]]></category>
		<category domain="http://resources.bnet.com/topic/alcatel.html"><![CDATA[Alcatel]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/echo.html"><![CDATA[Echo]]></category>
		<category domain="http://resources.bnet.com/topic/games.html"><![CDATA[Games]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[HARDWARE]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/storage.html"><![CDATA[Storage]]></category>
		<category domain="http://resources.bnet.com/topic/visa+inc..html"><![CDATA[Visa Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">V</category>
		<category domain="tickers">ALA,AMGN,NDAQ,V</category>
	</item>
	<item>
		<title><![CDATA[Ventura County Star, Calif., Business Briefs Column.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5553/is_200208/ai_n21661808]]></link>
		<description><![CDATA[Ventura County Star, Calif. Knight Ridder/Tribune Business News    Aug. 22--AMGEN STUDY CITED IN PRESTIGIOUS JOURNAL A two-year-old  study  used by Amgen Inc. to obtain regulatory approval for its new  anemia drug  Aranesp on Wednesday received renewed interest in a  prestigious medical ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 22 Aug 2002 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/anemia.html"><![CDATA[anemia]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/productivity.html"><![CDATA[PRODUCTIVITY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">AMGN,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Active pharmaceutical ingredient watch. (Markets: Life Sciences).(various briefs)(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200206/ai_n13211037]]></link>
		<description><![CDATA[AMGEN Inc. reports that the European Commission recommended  approval of Aranesp darbepoetin alfa for treating anemia in adult  cancer patients with non-hematological malignancies receiving  chemotherapy. Amgen's Neulasta pegfilgrastim was also re    AMGEN Inc. reports that the European Commission recommended  approval of Aranesp (darbepoetin...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 10 Jun 2002 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/life+science.html"><![CDATA[life science]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen's Epogen Successor Aranesp Gets FDA Approval.(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200109/ai_n13211115]]></link>
		<description><![CDATA[IN A MAJOR boost to its drug franchise, Amgen has received US  marketing authorization for Aranesp darbepoetin alfa, the successor to  its top-selling anemia drug Epogen epoetin alfa.      IN A MAJOR boost to its drug franchise, Amgen has received US  marketing authorization...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 24 Sep 2001 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Reports Solid 2Q Results Despite Delay of Aranesp US Launch.(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200108/ai_n13311584]]></link>
		<description><![CDATA[BIOTECH LEADER Amgen reported solid second quarter earnings,  beating analysts estimates on sales of its top-selling anemia drug  Epogen epoetin alfa and immunity-boosting drug Neupogen filgrastim.  Key to the company s future growth is Aranesp (d    BIOTECH LEADER Amgen reported solid second quarter earnings,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 06 Aug 2001 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/anemia.html"><![CDATA[anemia]]></category>
		<category domain="http://resources.bnet.com/topic/aranesp.html"><![CDATA[Aranesp]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
</channel>
</rss>
